- Raine AEG. Hypertension. Blood viscosity and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1988; 1: 97-100.
- Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985; 290: 428-32.
- Trip MD, Manger-Cats V, Van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
- Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and haemostasis in renal disease. Kidney Int 1994; 46: 287-96.
- Elwood PC, Beswick AD, Sharp DS, Yarnell JWG, Rogers S, Renaud S. Whole blood impedance platelet aggregometry and ischaemic heart disease. The Caerphilly Collaborative Heart Disease Study. Atherosclerosis 1990; 10: 1032-6.
- Saniabadi A, Lowe GDO, Madhok R, Spowart K, Shaw B, Barbenel JC, Forbes CD. Red blood cells mediate spontaneous aggregation of platelets in whole blood. Atherosclerosis 1987; 66: 175-80.
- Taylor JE, Henderson IS, Stewart WK, Belch JJF. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancer 1991; 338: 1361-2.
- Taylor JE, Belch JJF, McLaren M, Henderson IS, Stewart WK. Prothrombotic effect of erythropoietin therapy and erythropoietin withdrawal in haemodialysis patients. Kidney Int 1993; 44: 171-82.
- Gordge MP, Leaker BR, Rylance PB, Neild GH. Haemostatic activation and proteinuria as factors in the progression of chronic renal failure. Nephrol Dial Transplant 1991; 6: 21-6.
- Gordge MP, Rylance PB, Neild GH. Anti-platelet therapy in diabetic and non-diabetic progressive renal failure. Clin Nephrol 1992; 37: 53-5.
- Frampton G, Parbtani A, Marchesi D, Duffus P, Livio M, Remuzzi G, Cameron JS. In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. Kidney Int 1983; 23: 506-13.
- Capitanio A, Mannucci P, Ponticelli C, Pareti F. Detection of circulating released platelets after renal transplantation. Transplantation 1982; 33: 298-301.
- Cohen H, Neild GH, Patel R, Mackie IJ, Machin SJ. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res 1988; 49:91-101.
- Vanrenterghem Y, Roels L, Lerut T, Gruwez J, Michielsen P. Gresele P, Deckmyn H, Colucci M, Arnout J, Vermylen J. Thrombotic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; I: 999-1002.
- Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, Moorhead JF, Sweny P, Dandona P. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32: 889-895.
- Belch JJF, Zoma AA, Richards IM, McLaughlin K, Forbes CD, Sturrock RA. Vascular damage and factor-VIII related antigen on the rheumatic diseases. Rheumatol Int 1987; 7: 107-11.
- Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985; 290: 428-32.
- Armstrong R, May JA, Lsche W, Heptinstall S. Factors that contribute to spontaneous platelet aggregation and streptokinaseinduced aggregation in whole blood. Thromb Haemostas 1995; 73(2): 297-303.
- Clauss A. Gernnungs physiologishe schnell method zur bestimmung des fibrinogens. Acta Haematolog 1957; 17: 237-251.
- Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. The coagulolytic system and endothelial function in cyclosporin-treated kidney altograft recipients. Transplantation 1996; 62: 828-30.
- Dunnill MS. Histopathology of rejection. In: Morris PJ, ed., Kidney Transplantation Principles and Practice. Philadelphia: Saunders, 1988: 439-72.
- Conger JD, Kim GE, Robinette JB. Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 1994; 267: F443-9.
- Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34: 515-9.
- Neild GH, Rocchi G, Imberti L, Fumagalli F, Brown Z, Remuzzi G, Williams DG. Effect of cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res 1983; 32: 373-9.
- Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L. Plasma and platelet von Willebrand factor defects in uraemia. Am J Med 1988; 85: 806-10.
- Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron SJ. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986; 42(2): 150-3.
- Freiche JC, Lang J, Sedivy P, Touraine JL. Prolonged survival of renal transplants in nonimmunised and hyperimmunised rats receiving a platelet-activating factor antagonist. Transplantation 1985; 40: 124-5.
- Moran M, Mozes MF, Maddux MS, Veremis S, Bartkus C, Ketel B, Pollack P, Wallemark C, Jonasson O. Prevention of acute graft rejection by the prostaglandin El analogue misoprostol in renal transplant recipients treated with cyclosporine and prednisone. N Engl J Med 1990; 322: 1183-8.
- Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159-68.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research